Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
5T4 mAb - 01 | Lead | Solid Tumor | Ovarian cancer,Lung cancer |
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CHEK-ATP176 | Human | HEK293/Human TPBG Stable Cell Line | |||
TPG-R52H6 | Rat | Rat TPBG / 5T4 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
|
TPG-M5255 | Mouse | Mouse TPBG / 5T4 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
|
TPG-H82F6 | Human | Biotinylated Human TPBG / 5T4 protein, Fc,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
TPG-C52H3 | Cynomolgus / Rhesus macaque | Cynomolgus / Rhesus macaque TPBG / 5T4 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
TPG-M52H3 | Mouse | Mouse TPBG / 5T4 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
|
TPG-H5253 | Human | Human TPBG / 5T4 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
TPG-H52E5 | Human | Unconjugated Human TPBG / 5T4 Protein, His,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
TPG-H82Eb | Human | Biotinylated Human TPBG / 5T4 Protein, His,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
Expression analysis of human TPBG on HEK293/Human TPBG Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human TPBG Stable Cell Line or negative control cell using anti-human TPBG antibody followed by staining with PE anti-human IgG antibody.
Immobilized Cynomolgus / Rhesus macaque TPBG, His Tag (Cat. No. TPG-C52H3) at 1 μg/mL (100 μL/well) can bind Anti-TPBG Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).
The purity of Rat TPBG Protein, His Tag (Cat. No. TPG-R52H6) is more than 90% and the molecular weight of this protein is around 42-57 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Naptumomab estafenatox | TTS-CD3; ABR-217620 | Phase 2 Clinical | Active Biotech Ab | Carcinoma, Renal Cell; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung | Details |
ALG.APV-527 | ALG.APV 527; ADC-1016; ATOR-1016; ALG.APV-527; ALG-APV-527 | Phase 2 Clinical | Alligator Bioscience Ab, Aptevo Therapeutics Inc | Solid tumours; Neoplasms | Details |
JK-06 | JK-06 | Phase 2 Clinical | Xinlitai (Chengdu) Biological Technology Co Ltd | Solid tumours; Neoplasms | Details |
TUB-030 | TUB-030 | Phase 2 Clinical | Tubulis GmbH | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
ACR-246 | ACR246; ACR-246; ADC2154; ADC-2154 | Phase 2 Clinical | Hangzhou Adcoris Biopharmacy Co Ltd | Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Esophageal Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
SYD-1875 | SYD-1875 | Phase 1 Clinical | Synthon Bv | Solid tumours | Details |
ASN-004 | ASN-004 | Phase 1 Clinical | Asana Biosciences Llc | Solid tumours | Details |
Naptumomab estafenatox/Durvalumab | NTX-352 | Phase 1 Clinical | Neotx Therapeutics Ltd | Solid tumours | Details |
XB-010 | XB-010 | Phase 1 Clinical | Exelixis Inc | Solid tumours | Details |
FTL-008.16 | FTL-008.16; FTL008.16 | Phase 1 Clinical | Sound(Chengdu)Biopharmacauticals Co Ltd | Solid tumours | Details |
IBR-854 | IBR854; IBR-854 | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Solid tumours | Details |
CBA-1535 | CBA-1535 | Phase 1 Clinical | Chiome Bioscience Inc | Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung | Details |
Anti-5T4 CAR-raNK Cell Therapy | Phase 1 Clinical | Imbioray (Hangzhou) Biomedicine Co Ltd | Solid tumours | Details | |
Prostate cancer vaccine(inactivated viral)(University of Oxford) | Clinical | University Of Oxford | Prostatic Neoplasms | Details |
This web search service is supported by Google Inc.